Cost-effectiveness analysis of two interventions to promote physical activity in a multiethnic population at high risk of diabetes: an economic evaluation of the 48-month PROPELS randomized controlled trial
Primary resultResult — go to the resultICER £49 273 per QALY gainedAuthors' conclusion
We found that neither WA nor WA+ was cost-effective at a limit of £20 000 per QALY gained. Our threshold analysis showed that interventions to increase step count can be cost-effective at this limit if they achieve greater long-term maintenance of effect.
Study context
- Population
- Multiethnic population at high risk of T2D (PROPELS trial data)
- Comparison
- Walking Away and Walking Away Plus vs usual care
- Primary endpoint
- Lifetime costs, lifetime quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) vs usual care, compared with NICE willingness-to-pay of £20 000-£30 000 per QALY gained
- Follow-up
- Lifetime
Methodological detailseconomic evaluation of the PROPELS randomised controlled trial, model-based (adapted School for Public Health Research diabetes prevention model), lifetime horizon, scenario analyses, threshold analysis
- Economic evaluation of the PROPELS randomised controlled trial
- Model-based (adapted School for Public Health Research diabetes prevention model)
- Lifetime horizon
- Scenario analyses
- Threshold analysis
Primary result
As reported in the abstract
ICER
£49 273 per QALY gained
By group
Usual care
£22 598
Walking Away (WA)
£23 018
WA+
£22 945
Further findings
Scenario analyses
- In no scenario did WA or WA+ have an ICER below £20 000 per QALY gained
Threshold analysis · 4 years
- Physical activity (PA) intervention costing the same as WA+ would have ICER below £20 000/QALY with step-count increase 100% maintained at 4 years
- 500 steps per day
Original publication
Cost-effectiveness analysis of two interventions to promote physical activity in a multiethnic population at high risk of diabetes: an economic evaluation of the 48-month PROPELS randomized controlled trial. BMJ Open Diabetes Res Care. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →